Compound III (Merck MR antagonist)

Compound III is a potent and selective non-steroidal mineralocorticoid receptor (MR) antagonist developed by Merck Sharp & Dohme. Identified in medicinal chemistry research (specifically referenced in PMID 27551786), this small molecule was designed to overcome the clinical limitations of traditional steroidal MR antagonists, such as spironolactone and eplerenone, which can exhibit off-target effects or lower potency. By selectively blocking the mineralocorticoid receptor, Compound III inhibits the physiological actions of aldosterone, a hormone that contributes to hypertension, fibrosis, and organ damage when overexpressed. The compound has demonstrated efficacy in preclinical models of cardiovascular and renal diseases, suggesting potential utility in treating conditions like heart failure, hypertension, and chronic kidney disease.